Danaher Closes $9.9B Masimo Acquisition, Expanding Medical Device Monitoring Platform

The Quick Take

• Danaher Corporation completes its $9.9 billion acquisition of Masimo Corporation, expanding its medical devices footprint.
• DHR is listed as one of the best long-term stocks to buy according to hedge fund consensus.
• The deal is one of 2026's largest medtech acquisitions and reshapes the patient monitoring equipment market.

Danaher Corporation has completed its $9.9 billion acquisition of Masimo Corporation, a leading medical technology company specialising in patient monitoring equipment and non-invasive sensing. The deal represents a significant expansion of Danaher's life sciences and diagnostics platform, adding Masimo's pulse oximetry and signal extraction technology portfolio. Danaher has historically created value through the Danaher Business System — a lean manufacturing and operational improvement methodology — which it applies post-acquisition to integrate and improve acquired businesses, a playbook that has delivered consistent margin expansion across prior deals.

The Masimo acquisition reshapes the patient monitoring segment of the medical device industry. Masimo's core pulse oximetry technology is embedded across hospitals globally, creating a recurring revenue stream through sensor consumables. Danaher gains direct exposure to the growing hospital automation and remote patient monitoring market. Competitors including Medtronic, Philips Healthcare, and GE HealthCare face intensified competitive pressure in the monitoring segment. Private equity firms and strategic acquirers hunting medtech assets will face a narrower target set as Danaher's move raises the strategic premium on remaining independent patient monitoring platforms.

Watch for Danaher's post-close integration timeline and any revenue or cost synergy guidance — the DBS integration model typically projects 2-3 year payback on acquired asset efficiency improvements. Masimo's Q2 2026 revenue contribution will be the first test of deal value creation. The macro variable is the hospital capital spending environment: any tightening of hospital budgets — driven by insurance reimbursement changes, government healthcare cost pressures, or interest rate sensitivity on hospital balance sheets — would slow the upgrade cycles that make patient monitoring investments most attractive.

Synthesized from 1 source.